Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China
- By He Huang,
- Hao Liu,
- Zhengwei Zhu,
- Wenjun Wang,
- Bo Liang,
- Huayang Tang,
- Sen Yang,
- Yujun Sheng,
- Liangdan Sun
- and Xuejun Zhang
Pages 73 to 78
Cite this article
- HUANG, He,
- LIU, Hao,
- ZHU, Zhengwei,
- WANG, Wenjun,
- LIANG, Bo,
- TANG, Huayang,
- YANG, Sen,
- SHENG, Yujun,
- SUN, Liangdan
- and ZHANG, Xuejun,
- Huang, He.,
- et al.
- Huang, H.,
- Liu, H.,
- Zhu, Z.,
- Wang, W.,
- Liang, B.,
- Tang, H.,
- Yang, S.,
- Sheng, Y.,
- Sun, L.
- and Zhang, X.
https://doi.org/10.1684/ejd.2024.4599
Cite this article
- Huang, H.,
- Liu, H.,
- Zhu, Z.,
- Wang, W.,
- Liang, B.,
- Tang, H.,
- Yang, S.,
- Sheng, Y.,
- Sun, L.
- and Zhang, X.
- Huang, He.,
- et al.
- HUANG, He,
- LIU, Hao,
- ZHU, Zhengwei,
- WANG, Wenjun,
- LIANG, Bo,
- TANG, Huayang,
- YANG, Sen,
- SHENG, Yujun,
- SUN, Liangdan
- and ZHANG, Xuejun,
https://doi.org/10.1684/ejd.2024.4599
Psoriasis is a chronic immune-mediated skin disease with complex pathogenesis, multiple aetiological factors and a number of associated comorbidities [1, 2]. Affecting particular body parts, such as the scalp, nails or feet, psoriasis can be particularly challenging to treat [3]. Mutations in different loci are involved in the immune processes of psoriasis, including those affecting the human leukocyte antigen (HLA)-Cw6 and IL-23/IL-17A axis [4–6]. Clarification of the pathogenesis of psoriasis has led to effective biologic treatments, targeting tumour necrosis factor-alpha (TNF-α), both interleukin (IL)-12 and IL-23, and, most recently, IL-17 [7, 8] and IL-23 alone [9, 10].
Guselkumab (CNTO 1959, Janssen Research and Development) is a human monoclonal antibody that inhibits the intracellular and downstream signalling of IL-23, which is required for terminal differentiation and survival of T helper (Th) 17 cells [11]. Guselkumab offers better Psoriasis Area and Severity Index (PASI) response compared to many other treatments and demonstrates a promising safety profile, making it an effective treatment option for patients with active psoriatic arthritis, comparable to IL-17A and subcutaneous TNF inhibitors [12–14]. Despite this, the data on guselkumab as treatment for moderate-to-severe plaque psoriasis in China is limited [15].
Superior efficacy of guselkumab for moderate-to-severe psoriasis, compared to placebo, adalimumab and secukinumab, has been confirmed in three Phase III randomized controlled trials (RCTs): VOYAGE 1 [16], VOYAGE 2 [17] and ECLIPSE [18], respectively…
Publisher keywords: effectiveness, guselkumab, head, lower limb, psoriasis, trunk
Uploaded: 10/09/2024
https://doi.org/10.1684/ejd.2024.4599This article is available in conditional access
Buy this article
€25.00